NEKTAR THERAPEUTICS 8-K

What Happened

• Nektar Therapeutics (NKTR) filed a Form 8‑K on January 27, 2026 disclosing a Regulation FD quiet period. The quiet period begins January 27, 2026 and will continue until the public announcement of analyses of the 36‑week maintenance data from its Phase 2b REZOLVE‑AD study of rezpegaldesleukin. The company said its next planned investor communication is expected in February 2026 at the time of the Maintenance Data presentation.

Key Details

• Quiet period start date: January 27, 2026.
• Data referenced: analyses of the 36‑week maintenance period from the Phase 2b REZOLVE‑AD study.
• Drug/study: rezpegaldesleukin in patients with moderate‑to‑severe atopic dermatitis.
• Next planned investor communication: expected February 2026 (presentation of Maintenance Data).

Why It Matters

• The quiet period means Nektar will limit public commentary until the formal release of the maintenance data, so investors should not expect interim updates or management commentary before the February presentation. The filing signals timing for a material data event (the 36‑week maintenance results) that could affect the company’s clinical outlook and investor interest in the program.